Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.47 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317710 | 0.88 | ALDH1A1 (0.49) | CYP19A1KMT2ARECQL | |
| SCHEMBL10195593 | 0.80 | KMT2A (0.52) | KMT2ARECQLPROKR1 | |
| SCHEMBL10195711 | 0.80 | KDM2B (0.53) | KMT2APROKR1 | |
| SCHEMBL10194851 | 0.78 | GRM3 (0.65) | KMT2ARECQLPROKR1 | |
| SCHEMBL10195742 | 0.76 | ALDH1A1 (0.54) | KMT2A | |
| SCHEMBL14266348 | 0.75 | CYP19A1 (0.49) | CYP19A1KMT2ACYP2B6 | |
| SCHEMBL10195745 | 0.75 | KMT2A (0.47) | KMT2APROKR1 | |
| SCHEMBL10194852 | 0.75 | KMT2A (0.51) | KMT2APROKR1 | |
| SCHEMBL8540140 | 0.74 | HPGD (0.57) | CYP19A1 | |
| SCHEMBL14266524 | 0.73 | CYP2B6 (0.50) | CYP19A1CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | CYP19A1 512/4885KMT2A 3615/4885RECQL 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.